Alvine gobbles $21.5M to treat gastrointestinal disease
Alvine Pharmaceuticals, developer of drugs for autoimmune and gastrointestinal diseases, has raised $21.5 million more in first-round funding, bringing the total to $47.5 million. The San Carlos, Calif. received the expansion from Panorama Capital, InterWest Partners, Prospect Venture Partners, Sofinnova Ventures, Black River Asset Management and Flagship Ventures.
Next Story: TC50: CrowdFlower offers rich analytics for Mechanical Turks
Previous Story: Clearwire to bring long-range wireless web to Silicon Valley
About the Author, Camille Ricketts
Camille was the lead writer for GreenBeat until August 2010. To reach VentureBeat's current writers, email tips@venturebeat.com.
